David Walker, DO
Internal Medicine · Sheridan, WYNPI 1639142508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 27.1% of the total. Among internal medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$877
- GSK$499
- Lilly USA, LLC$456
- Novo Nordisk$315
- Amgen$143
- Abbott$120
- plus $827 from 19 others
What the payments were for
- Food & beverage$3,237100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $877 |
| GSK | 24 | $499 |
| Lilly USA, LLC | 31 | $456 |
| Novo Nordisk | 18 | $315 |
| Amgen | 8 | $143 |
| Abbott | 7 | $120 |
| Boehringer Ingelheim | 5 | $101 |
| Insmed, Inc. | 3 | $83 |
| Merck | 5 | $77 |
| AbbVie | 3 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Exact Sciences | 3 | $48 |
| Astellas Pharma US Inc | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Pfizer | 3 | $36 |
| Novartis | 2 | $36 |
| Bayer | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Eisai Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| IBSA Pharma Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Organon | 1 | $16 |
How this compares
$3,238 in reported general payments places this provider in the 95th percentile of 101 internal medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 288 | $240,299 |
| OzempicSemaglutide | 100 | $102,509 |
| FarxigaDapagliflozin Propanediol | 60 | $63,769 |
| MounjaroTirzepatide | 62 | $63,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $49,635 |
| XareltoRivaroxaban | 43 | $41,127 |
| JardianceEmpagliflozin | 33 | $35,465 |
| RybelsusSemaglutide | 15 | $28,858 |
| JanuviaSitagliptin Phosphate | 40 | $26,282 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $24,074 |
| TrulicityDulaglutide | 21 | $19,858 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $17,025 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $16,918 |
| Spiriva HandihalerTiotropium Bromide | 17 | $13,780 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $240,299288 claims |
| Novo NordiskOzempic, Rybelsus | $315 | $131,367115 claims |
| Lilly USA, LLCMounjaro, Trulicity | $456 | $83,19383 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $877 | $80,921101 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $499 | $62,23184 claims |
| Johnson & JohnsonXarelto | $19 | $41,12743 claims |
| Boehringer IngelheimJardiance | $101 | $35,46533 claims |
| MerckJanuvia | $77 | $26,28240 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $63 | $17,02519 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $5,62824 claims |
| AbbVieSynthroid | $76 | $3,12062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 internal medicine providers in Wyoming.
Other internal medicine in Sheridan
- Juli AckermanSheridan$3K
- Hannah HallSheridan$3K
- Kristopher SchamberSheridan$2K
- Derek RedingerSheridan$1K
- Erin HendersonSheridan$991
- Allison DawsonSheridan$684
- Sierra GrossSheridan$666
- Elise SylarSheridan$270
- Abigail TurnboughSheridan$144
- Kim FehirSheridan$126
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.